Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Andolfo, Immacolata ^a,b   Petrosino, Giuseppe ^a   Vecchione, Loredana ^c   De Antonellis, Pasqualino ^a   Capasso, Mario ^a   Montanaro, Donatella ^a   Gemei, Marica ^a   Troncone, Giancarlo ^a   Iolascon, Achille ^a,b   Orditura, Michele ^c   Ciardiello, Fortunato ^c   De Vita, Fernando ^c   Zollo, Massimo ^a,b  

^a CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

CTCs; DNA; ErbB2 copy number variation; Esophageal carcinoma cell free; Prognostic marker

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; VASCULOTROPIN; DNA; TUMOR MARKER; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; COPY NUMBER VARIATION; DNA EXTRACTION; DNA ISOLATION; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; MALE; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; BLOOD; CARCINOMA; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; ESOPHAGUS TUMOR; GENE DOSAGE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CARCINOMA; DISEASE-FREE SURVIVAL; DNA; EARLY DETECTION OF CANCER; ESOPHAGEAL NEOPLASMS; FEMALE; GENE DOSAGE; GENES, ERBB-2; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79953784640     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-126     Document Type: Article

References (50)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007, 18(3):581-592. 10.1093/annonc/mdl498, 17287242.
2. Lagergren J. Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk?. Gut 2005, 54(Suppl 1):i1-5. 10.1136/gut.2004.041517, 1867797, 15711002.
3. Bird-Lieberman EL, Fitzgerald RC. Early diagnosis of oesophageal cancer. Br J Cancer 2009, 101(1):1-6. 10.1038/sj.bjc.6605126, 2713695, 19513070.
4. Endo M, Kawano T. Detection and classification of early squamous cell esophageal cancer. Dis Esophagus 1997, 10(3):155-158.
5. Ancona E, Rampado S, Cassaro M, Battaglia G, Ruol A, Castoro C, Portale G, Cavallin F, Rugge M. Prediction of lymph node status in superficial esophageal carcinoma. Ann Surg Oncol 2008, 15(11):3278-3288. 10.1245/s10434-008-0065-1, 18726651.
6. Koppert LB, Wijnhoven BP, van Dekken H, Tilanus HW, Dinjens WN. The molecular biology of esophageal adenocarcinoma. J Surg Oncol 2005, 92(3):169-190. 10.1002/jso.20359, 16299787.
7. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004, 31(4):450-464. 10.1053/j.seminoncol.2004.04.021, 15297938.
8. Vallbohmer D, Lenz HJ. Predictive and prognostic molecular markers in outcome of esophageal cancer. Dis Esophagus 2006, 19(6):425-432. 10.1111/j.1442-2050.2006.00622.x, 17069584.
9. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344(11):783-792. 10.1056/NEJM200103153441101, 11248153.
10. Reichelt U, Duesedau P, Tsourlakis M, Quaas A, Link BC, Schurr PG, Kaifi JT, Gros SJ, Yekebas EF, Marx A, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod Pathol 2007, 20(1):120-129. 10.1038/modpathol.3800712, 17143264.
11. Stoecklein NH, Hosch SB, Bezler M, Stern F, Hartmann CH, Vay C, Siegmund A, Scheunemann P, Schurr P, Knoefel WT, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell 2008, 13(5):441-453. 10.1016/j.ccr.2008.04.005, 18455127.
12. Chiang PW, Beer DG, Wei WL, Orringer MB, Kurnit DM. Detection of erbB-2 amplifications in tumors and sera from esophageal carcinoma patients. Clin Cancer Res 1999, 5(6):1381-1386.
13. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1(1):27-31. 10.1038/nm0195-27, 7584949.
14. Risau W. Mechanisms of angiogenesis. Nature 1997, 386(6626):671-674. 10.1038/386671a0, 9109485.
15. He Y, Karpanen T, Alitalo K. Role of lymphangiogenic factors in tumor metastasis. Biochim Biophys Acta 2004, 1654(1):3-12.
16. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002, 2(10):795-803. 10.1038/nrc909, 12360282.
17. Mustonen T, Alitalo K. Endothelial receptor tyrosine kinases involved in angiogenesis. J Cell Biol 1995, 129(4):895-898. 10.1083/jcb.129.4.895, 2120485, 7538139.
18. Kitadai Y, Amioka T, Haruma K, Tanaka S, Yoshihara M, Sumii K, Matsutani N, Yasui W, Chayama K. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int J Cancer 2001, 93(5):662-666. 10.1002/ijc.1379, 11477575.
19. von Rahden BH, Stein HJ, Puhringer F, Koch I, Langer R, Piontek G, Siewert JR, Hofler H, Sarbia M. Coexpression of cyclooxygenases (COX-1, COX-2) and vascular endothelial growth factors (VEGF-A, VEGF-C) in esophageal adenocarcinoma. Cancer Res 2005, 65(12):5038-5044. 10.1158/0008-5472.CAN-04-1107, 15958546.
20. Krzystek-Korpacka M, Matusiewicz M, Diakowska D, Grabowski K, Blachut K, Banas T. Up-regulation of VEGF-C secreted by cancer cells and not VEGF-A correlates with clinical evaluation of lymph node metastasis in esophageal squamous cell carcinoma (ESCC). Cancer Lett 2007, 249(2):171-177. 10.1016/j.canlet.2006.08.011, 17011116.
21. Pathak AK, Bhutani M, Kumar S, Mohan A, Guleria R. Circulating cell-free DNA in plasma/serum of lung cancer patients as a potential screening and prognostic tool. Clin Chem 2006, 52(10):1833-1842.
22. Hoon DS, Spugnardi M, Kuo C, Huang SK, Morton DL, Taback B. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients. Oncogene 2004, 23(22):4014-4022. 10.1038/sj.onc.1207505, 2856469, 15064737.
23. Koyanagi K, Mori T, O'Day SJ, Martinez SR, Wang HJ, Hoon DS. Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients. Cancer Res 2006, 66(12):6111-6117. 10.1158/0008-5472.CAN-05-4198, 2856454, 16778184.
24. Andolfatto S, Namour F, Garnier AL, Chabot F, Gueant JL, Aimone-Gastin I. Genomic DNA extraction from small amounts of serum to be used for alpha1-antitrypsin genotype analysis. Eur Respir J 2003, 21(2):215-219. 10.1183/09031936.03.00044303, 12608432.
25. Taback B, Fujiwara Y, Wang HJ, Foshag LJ, Morton DL, Hoon DS. Prognostic significance of circulating microsatellite markers in the plasma of melanoma patients. Cancer Res 2001, 61(15):5723-5726.
26. Koike M, Hibi K, Kasai Y, Ito K, Akiyama S, Nakao A. Molecular detection of circulating esophageal squamous cell cancer cells in the peripheral blood. Clin Cancer Res 2002, 8(9):2879-2882.
27. Castaldo G, Tomaiuolo R, Sanduzzi A, Bocchino ML, Ponticiello A, Barra E, Vitale D, Bariffi F, Sacchetti L, Salvatore F. Lung cancer metastatic cells detected in blood by reverse transcriptase-polymerase chain reaction and dot-blot analysis. J Clin Oncol 1997, 15(11):3388-3393.
28. Klein CA, Stoecklein NH. Lessons from an aggressive cancer: evolutionary dynamics in esophageal carcinoma. Cancer Res 2009, 69(13):5285-5288. 10.1158/0008-5472.CAN-08-4586, 19549904.
29. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001, 37(Suppl 4):S9-15. 10.1016/S0959-8049(01)00231-3, 11597399.
30. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
31. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, Bell SM, Combaret V, Puisieux A, Mighell AJ, et al. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 2003, 3:18. 10.1186/1472-6750-3-18, 270040, 14552656.
32. Yuan JS, Reed A, Chen F, Stewart CN. Statistical analysis of real-time PCR data. BMC Bioinformatics 2006, 7:85. 10.1186/1471-2105-7-85, 1395339, 16504059.
33. Dhanasekaran S, Doherty TM, Kenneth J. Comparison of different standards for real-time PCR-based absolute quantification. J Immunol Methods 354(1-2):34-39. 10.1016/j.jim.2010.01.004, 20109462.
34. Godornes C, Leader BT, Molini BJ, Centurion-Lara A, Lukehart SA. Quantitation of rabbit cytokine mRNA by real-time RT-PCR. Cytokine 2007, 38(1):1-7. 10.1016/j.cyto.2007.04.002, 2041851, 17521914.
35. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer 2009, 9:6. 10.1186/1471-2407-9-6, 2648997, 19128465.
36. Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G. Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 2008, 15(1):69-79. 10.1245/s10434-007-9596-0, 17896140.
37. Kallergi G, Markomanolaki H, Giannoukaraki V, Papadaki MA, Strati A, Lianidou ES, Georgoulias V, Mavroudis D, Agelaki S. Hypoxia-inducible factor-1alpha and vascular endothelial growth factor expression in circulating tumor cells of breast cancer patients. Breast Cancer Res 2009, 11(6):R84. 10.1186/bcr2452, 2815547, 19919679.
38. Bang Y, Eric VC, Feyereislova A, Hyun C C, Shen L, Sawaki A, Lordick F, et al. for the ToGA Trial Investigators Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-97. 10.1016/S0140-6736(10)61121-X, 20728210, for the ToGA Trial Investigators.
39. Shih CH, Ozawa S, Ando N, Ueda M, Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin Cancer Res 2000, 6(3):1161-1168.
40. Banki F, Yacoub WN, Hagen JA, Mason RJ, Ayazi S, DeMeester SR, Lipham JC, Danenberg K, Danenberg P, DeMeester TR. Plasma DNA is more reliable than carcinoembryonic antigen for diagnosis of recurrent esophageal cancer. J Am Coll Surg 2008, 207(1):30-35. 10.1016/j.jamcollsurg.2008.01.004, 18589358.
41. Van der Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY. The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 2009, 100(8):1277-1286. 10.1038/sj.bjc.6605013, 2676551, 19367284.
42. Boni L, Cassinotti E, Canziani M, Dionigi G, Rovera F, Dionigi R. Free circulating DNA as possible tumour marker in colorectal cancer. Surg Oncol 2007, 16(Suppl 1):S29-31. 10.1016/j.suronc.2007.10.004, 18024018.
43. Diehl F, Schmidt K, Durkee KH, Moore KJ, Goodman SN, Shuber AP, Kinzler KW, Vogelstein B. Analysis of mutations in DNA isolated from plasma and stool of colorectal cancer patients. Gastroenterology 2008, 135(2):489-498. 10.1053/j.gastro.2008.05.039, 2820386, 18602395.
44. Tomita H, Ichikawa D, Ikoma D, Sai S, Tani N, Ikoma H, Fujiwara H, Kikuchi S, Okamoto K, Ochiai T, et al. Quantification of circulating plasma DNA fragments as tumor markers in patients with esophageal cancer. Anticancer Res 2007, 27(4C):2737-2741.
45. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, et al. Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med 2008, 359(4):366-377. 10.1056/NEJMoa0800668, 18596266.
46. Perego RA, Corizzato M, Brambilla P, Ferrero S, Bianchi C, Fasoli E, Signorini S, Torsello B, Invernizzi L, Bombelli S, et al. Concentration and microsatellite status of plasma DNA for monitoring patients with renal carcinoma. Eur J Cancer 2008, 44(7):1039-1047. 10.1016/j.ejca.2008.03.008, 18397824.
47. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, Ooi A, Fujii H. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer 2005, 92(7):1253-1260. 10.1038/sj.bjc.6602499, 2361961, 15785739.
48. Bresalier RS. Barrett's Esophagus and esophageal adenocarcinoma. Annu Rev Med 2009, 60:221-231. 10.1146/annurev.med.59.061206.112706, 18783330.
49. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 10(2):87-101. 10.1038/nrc2773, 2879265, 20094044.
50. Hongo M, Nagasaki Y, Shoji T. Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity. J Gastroenterol Hepatol 2009, 24(5):729-735. 10.1111/j.1440-1746.2009.05824.x, 19646015.